SYRESpyre Therapeutics, Inc.

Healthcare
$85.70+476% 1Y

The financials

Spyre Therapeutics, Inc. by the numbers

For the full year FY2025, revenue was $0 and net income −$155M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.

Spyre Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$42M−$42Mn/a
Net income−$36M−$37Mn/a
Diluted EPS−$0.35n/an/a

Business segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q3 2024Total $0.00
  • Development Fee And Royalty$0.00year on year n/a
Segment sum = 100% of reported consolidated revenue · Latest source: 10-K filed Feb 19, 2026, SEC EDGAR
On our screens:Most shorted stocks

Biotechnology

Ranks #191 of 196 by RyuScore

Compare peers
PCVX+9.7%
Vaxcyte, Inc.
IMVT+0.69%
Immunovant, Inc.
PTGX+2.7%
Protagonist Therapeutics, Inc.
RYTM+1.3%
Rhythm Pharmaceuticals, Inc.
ABVX-1.0%
ABIVAX Société Anonyme
IBRX+6.0%
ImmunityBio, Inc.